Increase of Cardiac Autoantibodies Against Beta-2-adrenergic Receptor During Acute Cellular Heart Transplant Rejection

Christian Salbach,Philipp Schlegel,Vera Stroikova,Matthias Helmschrott,Anna-Maria Mueller,Christel Weiß,Evangelos Giannitsis,Norbert Frey,Philip Raake,Ziya Kaya

DOI: https://doi.org/10.1097/tp.0000000000005062

2024-09-26

Transplantation

Abstract:For a selected group of end-stage heart failure (HF) patients, heart transplantation (HTx) remains the last available treatment option. 1 Here, acute transplant rejection represents a pivotal cause of impaired long-term outcomes. Within the first year after HTx, up to 40% of the patients develop an acute cellular rejection (ACR). 2 Despite the potentially fatal impact of an ACR, there is sparse knowledge about the prevalence and role of cardiac autoantibodies (aABs) in this process. Mechanistically, cardiac damage and cardiomyocyte cell death might cause a presentation of former unknown cellular antigens to the immune system, stimulating the production of cardiac aABs. In other circumstances, such as dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM), cardiac aABs against beta-1-adrenergic receptor (β-1AR) or troponin I (TnI) were shown to be associated with cardiac dysfunction and progressive HF. 3 , 4 In animal models, experimental immunization using peptide sequences of cardiac autoantigens is known to cause experimental autoimmune myocarditis (EAM) accompanied by HF and DCM phenotype within susceptible mouse strains. 5-8 Recent studies could identify certain immunogenic peptide sequences in common autoantigens such as TnI or cardiac myosin (CM), causing autoimmunity in animal models after immunization or exposition to the immune system. 8-11 Additionally, current evidence suggests a worse prognosis in HTx recipients with the presence of cardiac aAB. 12 However, accounting for the immunosuppression for prevention of fatal rejection, HTx patients represent a unique study population for detection of cardiac aABs. Current literature describes both, aAB directed against cardiac autoantigens of the vascular endothelium such as endothelin-1 type A receptor or vimentin, as well as aABs against structural cardiac proteins such as CM or lamin A/C. 12-14 Albeit, the knowledge about cardiac aAB in HTx recipients during ACR directed against structural proteins remains scarce and their potential impact is not yet elucidated. 12-17 Thus, this study aimed (1) to serve as a feasibility analysis for a screening of cardiac aABs directed against structural proteins in HTx patients using a peptide array approach and (2) to serve as hypothesis-generating approach for evidence of differently regulated cardiac aABs during ACR in HTx patients (ACR-HTx) compared with non-ACR-HTx.

immunology,surgery,transplantation